These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 34403012)

  • 1. Targeting DNA damage repair pathways in pancreas cancer.
    Crowley F; Park W; O'Reilly EM
    Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
    Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
    Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
    Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
    JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    Moffat GT; O'Reilly EM
    Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer.
    LaRose M; Manji GA; Bates SE
    Semin Oncol; 2024; 51(1-2):36-44. PubMed ID: 38171988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives.
    Perkhofer L; Gout J; Roger E; Kude de Almeida F; Baptista Simões C; Wiesmüller L; Seufferlein T; Kleger A
    Gut; 2021 Mar; 70(3):606-617. PubMed ID: 32855305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibition in treatment of pancreatic cancer.
    Hammel P; Zhang C; Matile J; Colle E; Hadj-Naceur I; Gagaille MP; Bouattour M; Cros J; de Mestier L; Lamuraglia M
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):939-945. PubMed ID: 32936674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer.
    Singh HM; Bailey P; Hübschmann D; Berger AK; Neoptolemos JP; Jäger D; Siveke J; Springfeld C
    Genes Chromosomes Cancer; 2021 May; 60(5):373-384. PubMed ID: 33341987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
    Singh RR; O'Reilly EM
    Drugs; 2020 May; 80(7):647-669. PubMed ID: 32306207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
    Das S; Cardin D
    Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of PARP inhibitors in
    Chi J; Chung SY; Parakrama R; Fayyaz F; Jose J; Saif MW
    Therap Adv Gastroenterol; 2021; 14():17562848211014818. PubMed ID: 34025781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
    Kasi A; Al-Jumayli M; Park R; Baranda J; Sun W
    J Pancreat Cancer; 2020; 6(1):107-115. PubMed ID: 33376937
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
    Singh RR; Goldberg J; Varghese AM; Yu KH; Park W; O'Reilly EM
    Cancer Treat Rev; 2019 May; 75():27-38. PubMed ID: 30927677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor.
    Borazanci E; Korn R; Liang WS; Guarnieri C; Haag S; Snyder C; Hendrickson K; Caldwell L; Von Hoff D; Jameson G
    Oncologist; 2020 Jan; 25(1):e60-e67. PubMed ID: 31391296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
    Sorscher S; Ramkissoon S
    Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
    Shui L; Li X; Peng Y; Tian J; Li S; He D; Li A; Tian B; Li M; Gao H; An N; Yi C; Cao D
    J Transl Med; 2021 Jul; 19(1):301. PubMed ID: 34247626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
    Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
    Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging strategies in BRCA-positive pancreatic cancer.
    Kowalewski A; Szylberg Ł; Saganek M; Napiontek W; Antosik P; Grzanka D
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1503-1507. PubMed ID: 29777302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.
    Gout J; Perkhofer L; Morawe M; Arnold F; Ihle M; Biber S; Lange S; Roger E; Kraus JM; Stifter K; Hahn SA; Zamperone A; Engleitner T; Müller M; Walter K; Rodriguez-Aznar E; Sainz B; Hermann PC; Hessmann E; Müller S; Azoitei N; Lechel A; Liebau S; Wagner M; Simeone DM; Kestler HA; Seufferlein T; Wiesmüller L; Rad R; Frappart PO; Kleger A
    Gut; 2021 Apr; 70(4):743-760. PubMed ID: 32873698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.